Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Adrian Uy

Internal Medicine Salem, VA Medical Doctor

NPI 1952392870 CMS profile 179884

1802 Braeburn Drive, Ste 410, Salem, VA 24153

Open in the dashboard

General payments

$7,681

393 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Adrian Uy of Salem, VA is reported in the CMS Open Payments database as having received $7,681 across 393 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,964 120
2024 General $2,051 108
2023 General $288 16
2022 General $261 12
2021 General $95 5
2020 General $379 24
2019 General $1,644 108

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Adrian Uy
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Adrian Uy were reported at $2,964. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Adrian Uy Internal Medicine median Middle half National median
2019 $1,644 $159 $48–$570 $163
2020 $379 $119 $33–$402 $114
2021 $95 $135 $37–$521 $132
2022 $261 $141 $42–$496 $149
2023 $288 $149 $45–$519 $160
2024 $2,051 $154 $47–$537 $164
2025 $2,964 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,249 51 payments
  2. Pfizer Inc. $896 63 payments
  3. Novo Nordisk Inc $818 42 payments
  4. AbbVie, Inc. $623 39 payments
  5. Lilly USA, LLC $478 24 payments
  6. ViiV Healthcare Company $379 12 payments
  7. Amgen Inc. $328 12 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $311 18 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $269 12 payments
  10. Gilead Sciences, Inc. $266 12 payments
  11. Other $2,064 108 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,652 390 payments
  2. Education $29 3 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $519 24 payments
  2. Ozempic $453 25 payments
  3. RYBELSUS $403 22 payments
  4. PREVNAR 20 $330 21 payments
  5. AIRSUPRA $322 9 payments
  6. NURTEC ODT $304 17 payments
  7. COMIRNATY $289 19 payments
  8. UBRELVY $288 14 payments
  9. XIFAXAN $278 16 payments
  10. ABRYSVO $276 18 payments
  11. Other $6,809 369 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 105 drugs

Part D claims

3,902

Median for Internal Medicine: 777

Drug cost

$340,729

Median for Internal Medicine: $73,373

Branded share of claims

19.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 55 $99,498
Wegovy Semaglutide Brand 15 $32,300
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 24 $24,169
Eliquis Apixaban Brand 18 $21,675
Xarelto Rivaroxaban Brand 15 $21,596
Jardiance Empagliflozin Brand 16 $20,799
Januvia Sitagliptin Phosphate Brand 16 $19,479
Tresiba Flextouch U-200 Insulin Degludec Brand 16 $13,877
Vascepa Icosapent Ethyl Brand 16 $10,758
Lacosamide Generic 33 $9,365

The 10 drugs with the highest cost, of 105 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$142,821

Of which drugs: $7,519

Medicare patients

263

Average age 75

Services billed

1,984

120 women, 143 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 42%
Diabetes 28%
Ischemic heart disease 21%
Chronic kidney disease 21%
Atrial fibrillation 16%
Osteoporosis 16%
Depression 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Sarscv2 vac 30mcg trs-suc im 91320 Office 20 20 $3,056
Vaccine for influenza for injection into muscle 90662 Office 38 38 $3,027
Vaccine for influenza for administration into muscle, 0.5 ml dosage 90656 Office 13 13 $263

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 32 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
APRETUDE
  • ViiV Healthcare Company $194
$194 — —
VRAYLAR
  • AbbVie, Inc. $165
$165 — —
RYBELSUS
  • Novo Nordisk Inc $119
$119 — —
UBRELVY
  • AbbVie, Inc. $95
$95 — —
Ozempic
  • Novo Nordisk Inc $95
$95 55 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 32 with Patron

Records

393 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record